Drugs / EYP001a
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04037618 | Jul 2019 | — | Enyo Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03976687 | Jun 2019 → May 2020 | metabolic dysfunction-associated steatohepatitis | Enyo Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03272009 | Sep 2017 → Jul 2018 | chronic hepatitis B virus infection | Enyo Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03320616 | Feb → Oct 2017 | chronic hepatitis B virus infection | Enyo Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03110276 | Aug 2016 → Mar 2017 | — | Enyo Pharma | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04365933 | May 2020 → Jun 2021 | chronic hepatitis B virus infection | Enyo Pharma | Completed | No outcome recorded |
| Phase 2 | NCT04465916 | May 2020 → Jun 2021 | chronic hepatitis B virus infection | Enyo Pharma | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-11-19 | Enyo Pharma | Regulatory Vonafexor accepted as the generic name for EYP001 by the WHO enyopharma.com ↗
We are pleased to announce that the World Health Organization (WHO) has accepted the international non-proprietary name (INN, or generic name) vonafexor for our FXR agonist lead candidate previously referred to as EYP001. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-11-19 | Enyo Pharma | Vonafexor accepted as the generic name for EYP001 by the WHO enyopharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EYP001a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04037618 ↗ |
| Action | Activate | “EYP001a is a selective, synthetic FXR agonist” NCT03110276 ↗ |
| Route | Oral | “Administered orally once daily.” NCT03110276 ↗ |